Ewing's sarcoma-Routine diagnostic utilization of MIC2 analysis: A pediatric oncology group/children's cancer group intergroup study

E. J. Perlman*, P. S. Dickman, F. B. Askin, H. E. Grier, J. S. Miser, M. P. Link

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

143 Scopus citations

Abstract

Ewing's sarcoma and peripheral neuroectodermal tumor (PNET) are small blue cell tumors with no reliable positive diagnostic markers. However, Ewing's sarcoma and PNET recently have been shown to strongly express an antigen determined by the MIC2 gene, whereas other blue cell tumors of childhood for the most part do not. MIC2 analysis therefore offers a distinctive addition to the panel of immunohistochemical stains used to differentiate among small blue cell tumors of childhood, since it represents the first positive marker for Ewing's sarcoma and PNET. This study addresses the reliability of MIC2 analysis using the monoclonal antibody 12E7 on tumors registered in the current Intergroup Ewing's Sarcoma protocol. Of 244 tumors, 221 (91%) showed a diffuse strong membranous pattern. The antibody appears to withstand all the fixation variables inherent in a multi-institutional study. We conclude that MIC2 expression is highly reliable as a positive marker for the Ewing's sarcoma/PNET family of tumors when the results are interpreted in the total context with clinical and pathologic parameters.

Original languageEnglish (US)
Pages (from-to)304-307
Number of pages4
JournalHuman pathology
Volume25
Issue number3
DOIs
StatePublished - Mar 1994

Keywords

  • 12E7
  • Ewing's sarcoma
  • HBA-71
  • MIC2
  • peripheral neuroectodermal tumor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Ewing's sarcoma-Routine diagnostic utilization of MIC2 analysis: A pediatric oncology group/children's cancer group intergroup study'. Together they form a unique fingerprint.

Cite this